Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
doi:10.22028/D291-38678
Dateien zu diesem Datensatz:
Datei | Beschreibung | Größe | Format | |
---|---|---|---|---|
cancers-15-00297-v2.pdf | 1,22 MB | Adobe PDF | Öffnen/Anzeigen |
Titel: | PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer : A Retrospective Study |
VerfasserIn: | Banda, Amina Privé, Bastiaan M. Allach, Youssra Uijen, Maike J. M. Peters, Steffie M. B. Loeff, Cato C. Gotthardt, Martin Muselaers, Constantijn H. J. Witjes, J. Alfred van Oort, Inge M. Sedelaar, J. P. Michiel Westdorp, Harm Mehra, Niven Khreish, Fadi Ezziddin, Samer Sabet, Amir Kreissl, Michael C. Winkens, Thomas Seifert, Philipp Janssen, Marcel J. R. van Gemert, Willemijn A. M. Nagarajah, James |
Sprache: | Englisch |
In: | |
Titel: | Cancers |
Bandnummer: | 15 (2023) |
Heft: | 1 |
Verlag/Plattform: | MDPI |
Erscheinungsjahr: | 2022 |
Freie Schlagwörter: | Actinium-225 Lutetium-177 early stage prostate cancer PSMA radioligand therapy |
DDC-Sachgruppe: | 610 Medizin, Gesundheit |
Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
Abstract: | Background: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a novel treatment for patients with castration-resistant prostate cancer (CRPC). Given the mode of action, patients in an earlier disease stage, such as hormone-sensitive prostate cancer (HSPC), are also likely to benefit from [177Lu]Lu-PSMA- (177Lu-PSMA) or [225Ac]Ac-PSMA-radioligand treatment (225Ac-PSMA). In this retrospective study, we analyzed the safety and efficacy of PSMARLT in early-stage and hormone-sensitive metastatic prostate cancer patients. Methods: A retrospective study was performed in patients who received 177Lu-PSMA and/or 225Ac-PSMA with early-stage metastatic prostate cancer. The primary outcome parameter evaluated in this study was the progression-free survival (PFS) after PSMA-RLT and toxicity according to the Common Terminology Criteria for Adverse Events. Secondary outcome parameters were prostate-specific antigen (PSA) response and the date of onset of CRPC state. Results: In total, 20 patients were included of which 18 patients received 177Lu-PSMA radioligand and two patients received tandem treatment with both 177Lu-PSMA and 225Ac-PSMA radioligands. Patients received a median of 2 treatment cycles (range 1–6) and a median activity of 6.2 GBq 177Lu-PSMA per cycle (interquartile range (IQR) 5.2–7.4 GBq). PSMA-RLT was overall well-tolerated. The most common grade 1–2 side effects were xerostomia (n = 6) and fatigue (n = 8), which were only temporarily reported. One patient that received 225Ac-PSMA developed grade 3–4 bone marrow toxicity. The median PFS was 12 months (95% confidence interval (CI), 4.09–19.9 months). Seventeen (85%) patients had a ≥50% PSA response following PSMA-RLT. One patient developed CRPC 9 months following PSMA-RLT. Conclusions: In this small cohort study, PSMA-RLT appeared safe and showed encouraging efficacy for (metastasized) early-stage and hormone-sensitive prostate cancer patients. Prospective studies are awaited and should include long-term follow-up. |
DOI der Erstveröffentlichung: | 10.3390/cancers15010297 |
Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-386782 hdl:20.500.11880/34879 http://dx.doi.org/10.22028/D291-38678 |
ISSN: | 2072-6694 |
Datum des Eintrags: | 16-Jan-2023 |
Bezeichnung des in Beziehung stehenden Objekts: | Supplementary Materials |
In Beziehung stehendes Objekt: | https://www.mdpi.com/article/10.3390/cancers15010297/s1 |
Fakultät: | M - Medizinische Fakultät |
Fachrichtung: | M - Radiologie |
Professur: | M - Prof. Dr. Samer Ezziddin |
Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons